Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Messiaen, Peter ^a   Wensing, Annemarie M J ^b   Fun, Axel ^b   Nijhuis, Monique ^b   Brusselaers, Nele ^a   Vandekerckhove, Linos ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEVER; GLOMERULUS FILTRATION RATE; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; INSOMNIA; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; NAUSEA; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872239331     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052562     Document Type: Review

References (83)

1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Accessible at http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. Accessed 16/10/2012 2012/10/16. Geneva.
2. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
3. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, et al. (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49: 1441-1449.
4. Department of Health and Human Services. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- October 14, 2011. Accessible at http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7. Accessed 2012/10/16.
5. European AIDS Clinical Society. EACS European Guidelines for treatment of HIV infected adults in Europe. Accessible at http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41. Accessed 2012/10/16.
6. Relevo R, Balshem H, (2011) Finding evidence for comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of clinical epidemiology 64: 1168-1177.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 6: e1000097.
8. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, et al. (2010) AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. Journal of clinical epidemiology 63: 513-523.
9. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22: 719-748.
10. Viera AJ, (2008) Odds ratios and risk ratios: what's the difference and why does it matter? Southern medical journal 101: 730-734.
11. US Department of Health and Human Services Food and Drug Administration CfDEaR (2002) Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf Accessed 2012/08/23.
12. Wittkop L, Smith C, Fox Z, Sabin C, Richert L, et al. (2010) Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical trials (London, England) 7: 19-35.
13. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, et al. (2012) A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV clinical trials 13: 119-130.
14. Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, et al. (2012) Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results- SINGLE (ING114467). Abstract H-556b. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco.
15. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, et al. (2010) Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 55: 39-48.
16. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796-806.
17. Rockstroh J, Lazarrin A, Zhao J, Rodgers A, DiNubile M, et al. (2011) Long-term Efficacy of Raltegravir (RAL) or Efavirenz (EFV) Combined with Tenofovir (TDF) and Emtricitabine (FTC) in Treatment-naive HIV-1 Patients: Wk-192 Subgroup Analyses from STARTMRK Study. Abstract-No: PE7.9/17. 13th European AIDS Clinical Society Conference. Belgrade.
18. Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, et al. (2011) Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53: 807-816.
19. Rockstroh J, DeJesus E, Saag M, Yazdanpanah Y, Lennox J, et al. (2012) Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naïve HIV-1-infected patients: final 5-year double-blind results from STARTMRK. Abstract LBPE19. XIX International AIDS Conference. Washington DC.
20. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2009) Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 52: 350-356.
21. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Journal of acquired immune deficiency syndromes (1999) 46: 125-133.
22. Gotuzzo E, Nguyen BY, Markowitz M, Mendo F, Ratanasuwan W, et al. (2011) Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naive HIV-1-infected patients; final analysis of protocol 004. Abstract no. EPDB0102 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome.
23. Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, et al. (2011) Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. The Lancet infectious diseases 11: 907-915.
24. Young B, Vanig T, DeJesus E, Hawkins T, St Clair M, et al. (2011) 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naive HIV-1-infected patients: the SHIELD trial. HIV Clin Trials 12: 228-233.
25. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, et al. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379: 2439-2448.
26. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, et al. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Aids 25: F7-12.
27. Rockstroh J, Felizarta F, Maggiolo F, Pulido F, Stellbrink H, et al. (2010) Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: Rapid and potent 24-week antiviral responses in SPRING-1 (ING112276). Abstract O50. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.
28. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, et al. (2011) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet infectious diseases 12: 111-118.
29. van Lunzen J, Maggiolo F, Phung B, Tsybakova O, Young B, et al. (2011) Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG, S/GSK1349572), a next generation integrase inhibitor (INI) in combination therapy in antiretroviral-naïve adults: 48 week results from SPRING-1 (ING112276). Abstract no. TUAB0102 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.
30. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2012) Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086). Abstract THLBB04. XIX International AIDS Conference. Wasgington DC.
31. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, et al. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379: 2429-2438.
32. Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, et al. (2011) Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results. HIV clinical trials 12: 255-267.
33. Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, et al. (2011) RADAR study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Abstract no. MOPE214. 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.
34. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al. (2011) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Aids 25: 2113-2122.
35. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, et al. (2010) Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 50: 605-612.
36. Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, et al. (2010) Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 53: 456-463.
37. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269.
38. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201: 814-822.
39. Canestri A, Blanc C, Wirden M, Peytavin G, Ktorza N, et al. (2008) Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir. Abstract P38. Nineth International Congress on Drug Therapy in HIV Infection. Glasgow.
40. Fagard C, Descamps D, Colin C, Taburet AM, Molina JM, et al. (2011) Long Term Follow-up of Patients Receiving Raltegravir, Etravirine and Darunavir/ritonavir in the ANRS 139 TRIO Trial. Abstract #549. 18th Conference on Retroviruses and Opportunistic Infections. Boston.
41. Nozza S, Galli L, Visco F, Soria A, Canducci F, et al. (2010) Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS (London, England) 24: 924-928.
42. Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, et al. (2010) Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scandinavian journal of infectious diseases 42: 527-532.
43. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, et al. (2012) Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 12: 27-35.
44. Margot NA, Rhee M, Szwarcberg J, Miller MD, GS-US-183-0145 Study Team (2012) Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-US-183-0145. Abstract TUPE050. XIX International AIDS Conference. Washington DC.
45. Eron JJ, Livrozet JM, Morlat M, Lazzarin A, Katlama C, et al. (2010) Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: Week 24 results of the VIKING study (ING112961). Abstract O51. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.
46. Soriano V, Cox J, Eron JJ, Kumar P, Katlama C, et al. (2011) Dolutegravir (DTG, S/GSK1349572) Treatment of Subjects with Raltegravir (RAL) Resistance: Viral Suppression at Week 24 in the VIKING Study. Abstract-No: PS1/2 13th European AIDS Clinical Society Conference. Belgrade.
47. Eron JJ, Kumar P, Lazzarin A, Richmond G, Soriano V, et al. (2011) Dolutegravir in Subjects with HIV Exhibiting RAL Resistance: Functional Monotherapy Results of VIKING Study Cohort II. Abstract no 151LB. 18th Conference on Retroviruses and Opportunistic Infections Boston.
48. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, et al. (2010) Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 375: 396-407.
49. Martinez E, Larrousse M, Llibre JM, Gutierrez F, Saumoy M, et al. (2011) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS (London, England) 24: 1697-1707.
50. Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, et al. (2011) Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 66: 2099-2106.
51. Harris M, Larsen G, Montaner JS, (2008) Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Aids 22: 1224-1226.
52. Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, et al. (2009) Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clin Trials 10: 432-438.
53. Talbot A, Machouf N, Thomas R, Marcotte S, Therrien R, et al. (2009) Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort. J Acquir Immune Defic Syndr 51: 362-364.
54. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, et al. (2009) Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr 51: 367-373.
55. Vispo E, Barreiro P, Maida I, Mena A, Blanco F, et al. (2010) Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV clinical trials 11: 197-204.
56. Di Giambenedetto S, Fabbiani M, Colafigli M, Bracciale L, d'Ettore G, et al. (2011) Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study. Abstract no. CDB365 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.
57. Reliquet V, Chirouze C, Muret P, Peytavin G, Ferré V, et al. (2011) Raltegravir (RAL) and nevirapine (NVP) dual therapy maintains virologic suppression in HIV-infected HAART-treated patients: 48-week results of a pilot study. Abstract no. CDB363 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.
58. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature medicine 16: 460-465.
59. Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, et al. (2011) Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. The Journal of infectious diseases 204: 1532-1540.
60. Cesar C, Patterson P, Vázquez ML, Zapiola I, Saracco M, et al. (2011) Raltegravir intensification in HIV-infected patients with immune discordant response to HAART. Abstract no. MOPE166. 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.
61. Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, et al. (2011) No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-infected Patients Receiving Antiretroviral Therapy. Journal of acquired immune deficiency syndromes (1999).
62. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS medicine 7.
63. Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, et al. (2010) Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 54: 389-393.
64. Lichtenstein K, Harbeck R, Nagabhushanam V, Hiserote M, Efaw B, et al. (2010) A pilot study to assess the immunological response when raltegravir is added to a virologically suppressed HAART regimen. Abstract no. CDB0165. XVIII International AIDS Conference. Vienna.
65. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, et al. (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clinical infectious diseases 50: 912-919.
66. Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, et al. (2012) Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. The Journal of infectious diseases 204: 1936-1945.
67. Allavena C, Mounoury O, Rodallec A, Dailly E, Jovelin T, et al. (2009) Raltegravir plus a boosted protease inhibitor: experience of a novel dual combination in HIV-infected antiretroviral-experienced patients. Abstract-No: PE7.9/17. 12th European AIDS Clinical Society Conference Koln.
68. Cordery DV, Hesse K, Amin J, Cooper DA, (2010) Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 15: 1035-1038.
69. Ripamonti D, Maggiolo F, Bombana E, Gregis G, Quinzan G, et al. (2009) Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients. Abstract no. MOPEB067. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
70. Tsukada K, Nishijima T, Gatanaga H, Kanaya F, Kikuchi Y, et al. (2011) Efficacy of NRTI-sparing regimen of raltegravir plus boosted darunavir in NRTI intolerant patients. Abstract no. CDB353 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.
71. Gardner EM, Melendez AG, Astiz M, Bray K, (2012) Adherence and Preexisting Major Protease Inhibitor Resistance Mutations are Associated with Virologic Failure of a Dual-Class Antiretroviral Regimen with Inhibitors of HIV-1 Viral Protease and Integrase. Journal of the International Association of Physicians in AIDS Care Chicago, Ill 11: 34-39.
72. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
73. Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, et al. (2011) Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrobial agents and chemotherapy 55: 321-325.
74. Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, et al. (2010) Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 65: 320-326.
75. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, et al. (2008) Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 82: 10366-10374.
76. Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, et al. (2011) Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. The Journal of infectious diseases 204: 1811-1815.
77. Hightower K, Wang R, Seki T, Kobayashi M, Underwood M (2011) Slow dissociation of Dolutegravir (S/GSK1349572) contributes to an improved resistance profile with integrase inhibitor-resistant mutants. Abstract O_02. 9th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. Paphos, Cyprus.
78. Clotet B, Katlama C, Soriano V, Lazzarin A, Richmond GJ, et al. (2011) HIV Integrase resistance and phenotypic susceptibility to Dolutegravir (DTG, S/GSK1349572) for subjects with virological failure on Raltegravir (RAL) Abstract O_03. 9th European Workshop on HIV & Hepatitis Treatment Strategies and Antiviral Drug Resistance. Paphos, Cyprus.
79. Qaqish R, van Wyk J, King MS, (2010) A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs twice daily lopinavir/ritonavir (LPV/r) regimens. Journal of the International AIDS Society 2010 (Suppl 4) (): P58.
80. Smith F, Hammerstrom T, Soon G, Zhou S, Chen B, et al. (2011) A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 45: 291-300.
81. Zhang W, Pannucci M, Guo J, Hall D (2011) Comparison of TLOVR Algorithm Versus Snapshot Approach for HIV Studies. Abstract- #301734. 2011 Joint Statistical Meetings. Miami.
82. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States-September 14, 2011. Accessible at http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed 2012/10/16.
83. Fallon JP, Kurusa G, Correll TA, Qaqish RB, Woodward WC, et al. (2010) Safety and efficacy of lopinavir/ritonavir (LPV/r) in combination with raltegravir (RAL) in HIV-infected subjects: 24 week interim analysis. Abstract no. THPE0070. XVIII International AIDS Conference. Vienna.